JP2012136519A5 - - Google Patents

Download PDF

Info

Publication number
JP2012136519A5
JP2012136519A5 JP2012004674A JP2012004674A JP2012136519A5 JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5 JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012004674 A JP2012004674 A JP 2012004674A JP 2012136519 A5 JP2012136519 A5 JP 2012136519A5
Authority
JP
Japan
Prior art keywords
antibody
domain
structures
terminal side
spacer polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012004674A
Other languages
English (en)
Japanese (ja)
Other versions
JP5901299B2 (ja
JP2012136519A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012004674A priority Critical patent/JP5901299B2/ja
Priority claimed from JP2012004674A external-priority patent/JP5901299B2/ja
Publication of JP2012136519A publication Critical patent/JP2012136519A/ja
Publication of JP2012136519A5 publication Critical patent/JP2012136519A5/ja
Application granted granted Critical
Publication of JP5901299B2 publication Critical patent/JP5901299B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012004674A 2006-03-03 2012-01-13 生物活性を強化した抗体改変体 Expired - Fee Related JP5901299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012004674A JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006057475 2006-03-03
JP2006057475 2006-03-03
JP2012004674A JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008502861A Division JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Publications (3)

Publication Number Publication Date
JP2012136519A JP2012136519A (ja) 2012-07-19
JP2012136519A5 true JP2012136519A5 (enExample) 2013-05-30
JP5901299B2 JP5901299B2 (ja) 2016-04-06

Family

ID=38459178

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008502861A Expired - Fee Related JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体
JP2012004674A Expired - Fee Related JP5901299B2 (ja) 2006-03-03 2012-01-13 生物活性を強化した抗体改変体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008502861A Expired - Fee Related JP5598894B2 (ja) 2006-03-03 2007-03-02 生物活性を強化した抗体改変体

Country Status (6)

Country Link
US (2) US20090304715A1 (enExample)
EP (2) EP2006305B1 (enExample)
JP (2) JP5598894B2 (enExample)
CA (1) CA2638804C (enExample)
ES (1) ES2602439T3 (enExample)
WO (1) WO2007100083A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2006305B1 (en) * 2006-03-03 2016-08-10 The Chemo-Sero-Therapeutic Research Institute Modified antibody with enhanced bioactivity
CN103897063B (zh) * 2007-06-01 2017-04-12 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010065578A2 (en) * 2008-12-04 2010-06-10 Leukosight Inc. POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
WO2012002562A1 (en) * 2010-06-30 2012-01-05 Tokyo University Of Science Educational Foundation Administrative Organization Modified protein therapeutics
EP3543257A1 (en) 2010-07-28 2019-09-25 Gliknik Inc. Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
EP2681239B8 (en) * 2011-02-28 2015-09-09 F. Hoffmann-La Roche AG Antigen binding proteins
KR20150058236A (ko) 2012-08-20 2015-05-28 글리크닉 인코포레이티드 항원 결합 및 다가 fc 감마 수용체 결합 활성을 가진 분자
WO2014115893A1 (ja) 2013-01-28 2014-07-31 株式会社イーベック ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片
CN105324166B (zh) 2013-07-12 2018-01-19 默克专利股份有限公司 利用活性炭从包含靶蛋白的样品去除片段
JP6904902B2 (ja) * 2014-12-05 2021-07-21 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ドメイン交換抗体
SI3325011T1 (sl) 2015-07-24 2021-02-26 Gliknik Inc. Fuzijski proteini humanih proteinskih fragmentov za tvorbo pravilnih multimeriziranih imunoglobulin FC sestavkov s povečanim vezanjem komplementa
EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CA3026420A1 (en) 2016-06-07 2017-12-14 Gliknik Inc. Cysteine-optimized stradomers
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
EP3551647A4 (en) 2016-12-09 2021-01-13 Gliknik Inc. MANUFACTURING OPTIMIZATION OF GL-2045, A MULTIMERIZING STRADOMER
AU2018205272A1 (en) * 2017-01-06 2019-07-25 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered Fc-antigen binding domain constructs
CA3105985A1 (en) * 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
CN119421953A (zh) 2022-01-28 2025-02-11 株式会社伊贝克 具有突变株交叉性的抗SARS－CoV－2人中和抗体及其抗原结合片段

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8824869D0 (en) 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
DE3908834A1 (de) 1989-03-17 1990-09-20 Hollingsworth Gmbh Vorrichtung zur ausscheidung von verunreinigungen eines faserverbandes an einer karde
AU2002250293B2 (en) * 2001-03-09 2007-10-11 Arnason, Barry G. Mr Polymeric immunoglobulin fusion proteins that target low-affinity FCGammaReceptors
WO2004029207A2 (en) * 2002-09-27 2004-04-08 Xencor Inc. Optimized fc variants and methods for their generation
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
EP2006305B1 (en) * 2006-03-03 2016-08-10 The Chemo-Sero-Therapeutic Research Institute Modified antibody with enhanced bioactivity

Similar Documents

Publication Publication Date Title
PH12013502568B1 (en) Anti-psgl-1 antibodies and uses thereof
JP2012116856A5 (enExample)
SG10201909806SA (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HRP20211594T1 (hr) Anti-pd1 protutijela i načini uporabe
JP2014526898A5 (enExample)
PE20200862A1 (es) Anticuerpos anti-trem2 y metodos relacionados
JP2012254083A5 (enExample)
JP2012034692A5 (enExample)
FI3736291T3 (fi) Anti-fcrh5-vasta-aineita
HRP20221141T1 (hr) Anti-lag3 protutijela
AR085383A1 (es) Anticuerpos contra el il33r humano y usos de los mismos
RU2018102526A (ru) Конструкции, направленные на комплексы пептида ny-eso-1/мнс, и их применение
HRP20170254T1 (hr) Humanizirana i kimerna monoklonska protutijela usmjerena na cd47
WO2013095738A3 (en) Monoclonal antibodies with altered affinities for human fcyri, fcyrllla, and c1q proteins
WO2017193032A3 (en) Bispecific binding proteins and uses thereof
HRP20231579T1 (hr) Anti-ctla-4 antitijela i postupci njihove upotrebe
HRP20161298T1 (hr) Novi antagonisti protutijela i njihovi fab fragmenti protiv gpvi i njihova uporaba
WO2015138600A3 (en) Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
PH12013502201A1 (en) Anti-b7-h3 antibody
IL258215B (en) Antibody anti-mesothelin, nucleic acid encoding said antibody, vector comprising said nucleic acid, host cell comprising said vector, method of preparing said antibody, and pharmaceutical composition for treating cancer or tumor comprising the antibody
HK1257441A1 (zh) 表达嵌合细胞内信号传导分子的细胞的方法和组合物
JP2013527761A5 (enExample)
JP2013241409A5 (enExample)
MX352338B (es) Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
HRP20161656T4 (hr) Sredstva za vezanje na cd33